Component

Human organic anion transporting polypeptide 2B1 / SLCO2B1

Human organic anion transporting polypeptide 2B1 / SLCO2B1. Species, exposure and limitations are retained in each linked claim.

8 recorded relationships. Experimental role, claim status and evidence remain attached to each record.

Read recorded mechanisms Open recursive mind map

How nutrients influence it

Every nutrient with a recorded effect on this component, credited to the nutrient that acted rather than the chapter that recorded it. Open a nutrient to see the findings and the conditions they were measured under.

How nutrients reach it in more than one step

Chains of two or more recorded steps that end here, grouped by the nutrient they start from. Each step is a separate finding, so a chain is a route a mechanism could take, not proof that it does.

Tracing routes…

What it does

Every recorded relationship this component is part of, grouped by its role. Plain wording comes first; the technical statement follows.

Recorded relationships

What it acts on

  1. Human SLCO2B1 transported Luteolin 3′-O-glucuronide in the fluorescence-based uptake assay.

    Human organic anion transporting polypeptide 2B1 / SLCO2B1 → Luteolin 3′-O-glucuronide source_derived_draftungraded
    Experimental context and source evidence
    evidence_access
    Primary abstract
    experimental_model
    Living-cell uptake using 2-APB fluorescence enhancement.
    limitations
    Transport capacity is not clinical efficacy or net organ flux.
    nutrient_topic
    Luteolin collection; molecular form, preparation, species, exposure and manipulation remain explicit. · Luteolin / 3′,4′,5,7-tetrahydroxyflavone
    plain_language
    A circulating conjugate has a route into cells.
    primary_references
    The 2-aminoethyl diphenylborinate-based fluorescent method identifies quercetin and luteolin metabolites as substrates of Organic anion transporting polypeptides, OATP1B1 and OATP2B1. · 2024 · https://pubmed.ncbi.nlm.nih.gov/38437885/ · DOI 10.1016/j.ejps.2024.106740
    transport_effect
    raises Measured in a fluorescence-based uptake assay.
    transport_pool
    the expressing cell Measured in a fluorescence-based uptake assay.

    Luteolin: metabolism, immune signaling, redox chemistry and cross-nutrient mechanisms (2026-09-19) · lines 196–202

    AI-assisted research curation; primary-abstract references and experimental limitations individually identified. Not publisher full text. · supports · Living-cell uptake using 2-APB fluorescence enhancement. · source_derived_draft · unverified_draft

    ## luteolin-slco2b1-3g A circulating conjugate has a route into cells. Human SLCO2B1 transported Luteolin 3′-O-glucuronide in the fluorescence-based uptake assay. Model: Living-cell uptake using 2-APB fluorescence enhancement. Limitations: Transport capacity is not clinical efficacy or net organ flux. Evidence access: Primary abstract The 2-aminoethyl diphenylborinate-based fluorescent method identifies quercetin and luteolin metabolites as substrates of Organic anion transporting polypeptides, OATP1B1 and OATP2B1. · 2024 · https://pubmed.ncbi.nlm.nih.gov/38437885/ · DOI 10.1016/j.ejps.2024.106740
    Complete structured claim and evidence

  2. Human SLCO2B1 transported Luteolin 3′-O-sulfate in the fluorescence-based uptake assay.

    Human organic anion transporting polypeptide 2B1 / SLCO2B1 → Luteolin 3′-O-sulfate source_derived_draftungraded
    Experimental context and source evidence
    evidence_access
    Primary abstract
    experimental_model
    Living-cell uptake using 2-APB fluorescence enhancement.
    limitations
    Transport capacity is not clinical efficacy or net organ flux.
    nutrient_topic
    Luteolin collection; molecular form, preparation, species, exposure and manipulation remain explicit. · Luteolin / 3′,4′,5,7-tetrahydroxyflavone
    plain_language
    A circulating conjugate has a route into cells.
    primary_references
    The 2-aminoethyl diphenylborinate-based fluorescent method identifies quercetin and luteolin metabolites as substrates of Organic anion transporting polypeptides, OATP1B1 and OATP2B1. · 2024 · https://pubmed.ncbi.nlm.nih.gov/38437885/ · DOI 10.1016/j.ejps.2024.106740
    transport_effect
    raises Measured in a fluorescence-based uptake assay.
    transport_pool
    the expressing cell Measured in a fluorescence-based uptake assay.

    Luteolin: metabolism, immune signaling, redox chemistry and cross-nutrient mechanisms (2026-09-19) · lines 212–218

    AI-assisted research curation; primary-abstract references and experimental limitations individually identified. Not publisher full text. · supports · Living-cell uptake using 2-APB fluorescence enhancement. · source_derived_draft · unverified_draft

    ## luteolin-slco2b1-3s A circulating conjugate has a route into cells. Human SLCO2B1 transported Luteolin 3′-O-sulfate in the fluorescence-based uptake assay. Model: Living-cell uptake using 2-APB fluorescence enhancement. Limitations: Transport capacity is not clinical efficacy or net organ flux. Evidence access: Primary abstract The 2-aminoethyl diphenylborinate-based fluorescent method identifies quercetin and luteolin metabolites as substrates of Organic anion transporting polypeptides, OATP1B1 and OATP2B1. · 2024 · https://pubmed.ncbi.nlm.nih.gov/38437885/ · DOI 10.1016/j.ejps.2024.106740
    Complete structured claim and evidence

  3. Human SLCO2B1 transported Luteolin 7-O-glucuronide in the fluorescence-based uptake assay.

    Human organic anion transporting polypeptide 2B1 / SLCO2B1 → Luteolin 7-O-glucuronide source_derived_draftungraded
    Experimental context and source evidence
    evidence_access
    Primary abstract
    experimental_model
    Living-cell uptake using 2-APB fluorescence enhancement.
    limitations
    Transport capacity is not clinical efficacy or net organ flux.
    nutrient_topic
    Luteolin collection; molecular form, preparation, species, exposure and manipulation remain explicit. · Luteolin / 3′,4′,5,7-tetrahydroxyflavone
    plain_language
    A circulating conjugate has a route into cells.
    primary_references
    The 2-aminoethyl diphenylborinate-based fluorescent method identifies quercetin and luteolin metabolites as substrates of Organic anion transporting polypeptides, OATP1B1 and OATP2B1. · 2024 · https://pubmed.ncbi.nlm.nih.gov/38437885/ · DOI 10.1016/j.ejps.2024.106740
    transport_effect
    raises Measured in a fluorescence-based uptake assay.
    transport_pool
    the expressing cell Measured in a fluorescence-based uptake assay.

    Luteolin: metabolism, immune signaling, redox chemistry and cross-nutrient mechanisms (2026-09-19) · lines 204–210

    AI-assisted research curation; primary-abstract references and experimental limitations individually identified. Not publisher full text. · supports · Living-cell uptake using 2-APB fluorescence enhancement. · source_derived_draft · unverified_draft

    ## luteolin-slco2b1-7g A circulating conjugate has a route into cells. Human SLCO2B1 transported Luteolin 7-O-glucuronide in the fluorescence-based uptake assay. Model: Living-cell uptake using 2-APB fluorescence enhancement. Limitations: Transport capacity is not clinical efficacy or net organ flux. Evidence access: Primary abstract The 2-aminoethyl diphenylborinate-based fluorescent method identifies quercetin and luteolin metabolites as substrates of Organic anion transporting polypeptides, OATP1B1 and OATP2B1. · 2024 · https://pubmed.ncbi.nlm.nih.gov/38437885/ · DOI 10.1016/j.ejps.2024.106740
    Complete structured claim and evidence

  4. Sulfasalazine was transported by OATP2B1 in transfected cells, Km 1.7 +/- 0.3 micromolar.

    Human organic anion transporting polypeptide 2B1 / SLCO2B1 → Human transporter-mediated sulfasalazine uptake in vitro source_derived_draftungraded
    Experimental context and source evidence
    evidence_span
    {"source_cache": "artifacts/curcumin-research/22300367.abstract.txt", "locator": "Primary indexed abstract; zero-based, end-exclusive Unicode character offsets", "file_sha256": "a8ec64e7dff4a52838fa067fdc9418ee3ebe768c4a4d53629bd84f9f0ffe67fe", "start_char": 0, "end_char": 1713, "text_sha256": "a8ec64e7dff4a52838fa067fdc9418ee3ebe768c4a4d53629bd84f9f0ffe67fe"}
    experimental_model
    Human pharmacokinetics, transporter vesicles and mouse knockout experiment
    exposure
    Human: curcumin 2 g before sulfasalazine 100 micrograms or 2 g; eight participants. Mouse: 300-400 mg/kg curcumin
    limitations
    Small dose- and formulation-specific drug study. Transporter inference is supported by separate assays, not a universal effect on every BCRP substrate.
    nutrient_topic
    Curcumin research collection; topical membership is not evidence of a direct dietary effect. · Curcumin
    organism
    Human transporter/human participants; mouse claims separately scoped
    plain_language
    An uptake transporter also affects the drug's handling.
    primary_references
    [curcumin-p22300367] Pharmacokinetic interaction study of sulphasalazine in healthy subjects and the impact of curcumin as an in vivo inhibitor of BCRP. (2012). https://pubmed.ncbi.nlm.nih.gov/22300367/ DOI: 10.1111/j.1476-5381.2012.01887.x
    tissue_or_cell_type
    Intestinal drug transport and plasma

    Curcumin: metabolism, signaling and nutrient connections (2026-09-17) · lines 788–799

    AI-assisted literature curation; primary study URLs and scope retained in the document and extraction. Not publisher full text. · supports · Human pharmacokinetics, transporter vesicles and mouse knockout experiment · source_derived_draft · unverified_draft

    ### curcumin-oatp-uptake Sulfasalazine was transported by OATP2B1 in transfected cells, Km 1.7 +/- 0.3 micromolar. Condition category: normal nutrient_topic: Curcumin research collection; topical membership is not evidence of a direct dietary effect. plain_language: An uptake transporter also affects the drug's handling. organism: Human transporter/human participants; mouse claims separately scoped tissue_or_cell_type: Intestinal drug transport and plasma experimental_model: Human pharmacokinetics, transporter vesicles and mouse knockout experiment limitations: Small dose- and formulation-specific drug study. Transporter inference is supported by separate assays, not a universal effect on every BCRP substrate. exposure: Human: curcumin 2 g before sulfasalazine 100 micrograms or 2 g; eight participants. Mouse: 300-400 mg/kg curcumin evidence_span: {"source_cache": "artifacts/curcumin-research/22300367.abstract.txt", "locator": "Primary indexed abstract; zero-based, end-exclusive Unicode character offsets", "file_sha256": "a8ec64e7dff4a52838fa067fdc9418ee3ebe768c4a4d53629bd84f9f0ffe67fe", "start_char": 0, "end_char": 1713, "text_sha256": "a8ec64e7dff4a52838fa067fdc9418ee3ebe768c4a4d53629bd84f9f0ffe67fe"} [curcumin-p22300367] Pharmacokinetic interaction study of sulphasalazine in healthy subjects and the impact of curcumin as an in vivo inhibitor of BCRP. (2012). https://pubmed.ncbi.nlm.nih.gov/22300367/ DOI: 10.1111/j.1476-5381.2012.01887.x
    Complete structured claim and evidence

  5. Myricetin 3′-O-sulfate was a substrate of human SLCO2B1.

    Human organic anion transporting polypeptide 2B1 / SLCO2B1 → Myricetin 3′-O-sulfate source_derived_draftungraded
    Experimental context and source evidence
    evidence_access
    Primary full text
    experimental_model
    Overexpressing-cell uptake with flavonoid fluorescence method.
    limitations
    Not a quantified human tissue delivery rate.
    nutrient_topic
    Myricetin collection; molecular form, preparation, species, exposure and manipulation remain explicit. · Myricetin
    plain_language
    The sulfate is transported, not simply inactive waste.
    primary_references
    Interaction of myricetin, ampelopsin (dihydromyricetin), and their sulfate metabolites with serum albumin, cytochrome P450 (CYP2C9, 2C19, and 3A4) enzymes, and organic anion-transporting polypeptides (OATP1B1 and OATP2B1). · 2024 · https://pubmed.ncbi.nlm.nih.gov/39344282/ · DOI 10.1002/prp2.70021
    transport_effect
    raises Recorded as a substrate in the OATP2B1 uptake assay.
    transport_pool
    the expressing cell Recorded as a substrate in the OATP2B1 uptake assay.

    Myricetin: metabolism, immune signaling, redox chemistry and cross-nutrient mechanisms (2026-09-19) · lines 212–218

    AI-assisted research curation; primary references, access levels and experimental limitations individually identified. Not publisher full text. · supports · Overexpressing-cell uptake with flavonoid fluorescence method. · source_derived_draft · unverified_draft

    ## myricetin-sulfate-uptake-slco2b1 The sulfate is transported, not simply inactive waste. Myricetin 3′-O-sulfate was a substrate of human SLCO2B1. Model: Overexpressing-cell uptake with flavonoid fluorescence method. Limitations: Not a quantified human tissue delivery rate. Evidence access: Primary full text Interaction of myricetin, ampelopsin (dihydromyricetin), and their sulfate metabolites with serum albumin, cytochrome P450 (CYP2C9, 2C19, and 3A4) enzymes, and organic anion-transporting polypeptides (OATP1B1 and OATP2B1). · 2024 · https://pubmed.ncbi.nlm.nih.gov/39344282/ · DOI 10.1002/prp2.70021
    Complete structured claim and evidence

What acts on it

  1. The parent inhibited human SLCO2B1 transport in vitro, IC50 0.4 micromolar.

    Myricetin → Human organic anion transporting polypeptide 2B1 / SLCO2B1 source_derived_draftungraded
    Experimental context and source evidence
    evidence_access
    Primary full text
    experimental_model
    Human transporter-overexpressing cells.
    limitations
    Probe-substrate potency is not a measured clinical drug interaction.
    nutrient_topic
    Myricetin collection; molecular form, preparation, species, exposure and manipulation remain explicit. · Myricetin
    plain_language
    Transport competition can depend on the metabolite.
    primary_references
    Interaction of myricetin, ampelopsin (dihydromyricetin), and their sulfate metabolites with serum albumin, cytochrome P450 (CYP2C9, 2C19, and 3A4) enzymes, and organic anion-transporting polypeptides (OATP1B1 and OATP2B1). · 2024 · https://pubmed.ncbi.nlm.nih.gov/39344282/ · DOI 10.1002/prp2.70021

    Myricetin: metabolism, immune signaling, redox chemistry and cross-nutrient mechanisms (2026-09-19) · lines 116–122

    AI-assisted research curation; primary references, access levels and experimental limitations individually identified. Not publisher full text. · supports · Human transporter-overexpressing cells. · source_derived_draft · unverified_draft

    ## myricetin-parent-slco2b1 Transport competition can depend on the metabolite. The parent inhibited human SLCO2B1 transport in vitro, IC50 0.4 micromolar. Model: Human transporter-overexpressing cells. Limitations: Probe-substrate potency is not a measured clinical drug interaction. Evidence access: Primary full text Interaction of myricetin, ampelopsin (dihydromyricetin), and their sulfate metabolites with serum albumin, cytochrome P450 (CYP2C9, 2C19, and 3A4) enzymes, and organic anion-transporting polypeptides (OATP1B1 and OATP2B1). · 2024 · https://pubmed.ncbi.nlm.nih.gov/39344282/ · DOI 10.1002/prp2.70021
    Complete structured claim and evidence

  2. The sulfate inhibited human SLCO2B1 transport in vitro, IC50 0.3 micromolar.

    Myricetin 3′-O-sulfate → Human organic anion transporting polypeptide 2B1 / SLCO2B1 source_derived_draftungraded
    Experimental context and source evidence
    evidence_access
    Primary full text
    experimental_model
    Human transporter-overexpressing cells.
    limitations
    Probe-substrate potency is not a measured clinical drug interaction.
    nutrient_topic
    Myricetin collection; molecular form, preparation, species, exposure and manipulation remain explicit. · Myricetin
    plain_language
    Transport competition can depend on the metabolite.
    primary_references
    Interaction of myricetin, ampelopsin (dihydromyricetin), and their sulfate metabolites with serum albumin, cytochrome P450 (CYP2C9, 2C19, and 3A4) enzymes, and organic anion-transporting polypeptides (OATP1B1 and OATP2B1). · 2024 · https://pubmed.ncbi.nlm.nih.gov/39344282/ · DOI 10.1002/prp2.70021

    Myricetin: metabolism, immune signaling, redox chemistry and cross-nutrient mechanisms (2026-09-19) · lines 164–170

    AI-assisted research curation; primary references, access levels and experimental limitations individually identified. Not publisher full text. · supports · Human transporter-overexpressing cells. · source_derived_draft · unverified_draft

    ## myricetin-sulfate-slco2b1 Transport competition can depend on the metabolite. The sulfate inhibited human SLCO2B1 transport in vitro, IC50 0.3 micromolar. Model: Human transporter-overexpressing cells. Limitations: Probe-substrate potency is not a measured clinical drug interaction. Evidence access: Primary full text Interaction of myricetin, ampelopsin (dihydromyricetin), and their sulfate metabolites with serum albumin, cytochrome P450 (CYP2C9, 2C19, and 3A4) enzymes, and organic anion-transporting polypeptides (OATP1B1 and OATP2B1). · 2024 · https://pubmed.ncbi.nlm.nih.gov/39344282/ · DOI 10.1002/prp2.70021
    Complete structured claim and evidence

Where it participates (unsigned role)

  1. Selected naringenin sulfate or glucuronide conjugates potently inhibited OATP1B1 and/or OATP2B1 in vitro.

    Naringenin sulfate conjugates → Human OATP1B1/OATP2B1 transport activity source_derived_draftungraded
    Experimental context and source evidence
    dose
    Naringenin metabolite concentration-response
    duration
    Acute
    evidence_access
    Primary PubMed abstract and indexed metadata reviewed. Full-text method details not stated here remain unresolved.
    evidence_scope
    literature_reviewed; model-specific source-derived curation
    experimental_model
    Transporter expression assays
    limitations
    The abstract does not assign every conjugate to each transporter or establish interaction at human free concentrations.
    nutrient_topic
    Naringenin chapter; interacting nutrients, drugs, peptides and proteins retain their experimental settings. · Naringenin
    organism
    Transporter expression assays
    plain_language
    Selected naringenin sulfate or glucuronide conjugates potently inhibited OATP1B1 and/or OATP2B1 in vitro.
    primary_references
    Interaction of luteolin, naringenin, and their sulfate and glucuronide conjugates with human serum albumin, cytochrome P450 (CYP2C9, CYP2C19, and CYP3A4) enzymes and organic anion transporting polypeptide (OATP1B1 and OATP2B1) transporters. (2023). https://pubmed.ncbi.nlm.nih.gov/36481402/ DOI: 10.1016/j.biopha.2022.114078
    route
    In vitro
    tissue
    OATP1B1 and OATP2B1 transport

    Naringenin: mechanism of action and interactions (2026-09-20) · lines 88–97

    Original AI-assisted source-specific curation with primary-study citations, model, exposure, route, duration, negative findings and limitations preserved. Not publisher full text. · supports · Transporter expression assays · source_derived_draft · unverified_draft

    ## naringenin-oatp-inhibition Selected naringenin sulfate or glucuronide conjugates potently inhibited OATP1B1 and/or OATP2B1 in vitro. Model/species: Transporter expression assays Tissue/system: OATP1B1 and OATP2B1 transport Exposure: Naringenin metabolite concentration-response Route: In vitro Duration: Acute Limits: The abstract does not assign every conjugate to each transporter or establish interaction at human free concentrations. Primary reference: Interaction of luteolin, naringenin, and their sulfate and glucuronide conjugates with human serum albumin, cytochrome P450 (CYP2C9, CYP2C19, and CYP3A4) enzymes and organic anion transporting polypeptide (OATP1B1 and OATP2B1) transporters. (2023). https://pubmed.ncbi.nlm.nih.gov/36481402/ DOI: 10.1016/j.biopha.2022.114078 Access: Primary PubMed abstract and indexed metadata reviewed. Full-text method details not stated here remain unresolved.
    Complete structured claim and evidence

In the sources

Preserved passages that mention this component, quoted exactly. Open one to read it in context.

    This is a research prototype built from draft material. It is not medical advice, and its statements still await verification against the original studies.

    Evidence, AI assistance and curation standards